Update from the IDENTIFY Study Within a year, over 11,000 patients across 26 countries were recruited
has been published in European Urology Focus (doi: 10.1016/j.euf.2022.06.001), and the prediction model is available to use as an app called IDENTIFY risk calculator on Apple and Android. Results of external validation: We performed an external validation in a new prospective cohort collected between February and September 2022. We had data from over 3,500 patients in 26 countries, different from those within the development cohort. The development and validation cohorts were well matched with regards to patient characteristics and demographics. We were able to ascertain that the calculator performed well and had an area under the curve of 0.78. Furthermore, the calibration slope, which looks at observed versus predicted cancers, was close to 1 at 0.95. We are in the process of documenting these findings and publishing the paper, then determining which prediction model can be used reliably and dispersed through other platforms such as MDCalc. “We were able to ascertain that the calculator performed well and had an area under the curve of 0.78.” Our vision is that the calculator can be used in the haematuria diagnostic pathway to risk-stratify patients for better use and efficiency of resources, as well as improving the speed of diagnosing urinary tract malignancy for earlier treatment and better prognosis.
Mr. Sinan Khadhouri Aberdeen Royal Infirmary Aberdeen (GB)
sinan.khadhouri@ doctors.org.uk
The external validation of the IDENTIFY risk calculator shows good prediction of urinary tract cancer in patients referred to secondary care with visible or non-visible haematuria. The IDENTIFY study is the biggest international prospective observational study on patients referred to secondary care with suspected urinary tract cancer. We included adults aged 16 years and older and excluded patients with a prior diagnosis of any urological malignancy. Within a year, we recruited just over 11,000 patients across 26 countries. Using this data we developed a cancer prediction model using common patient characteristics. This
Table 1: Results of the external validation
Map showing the geographic spread of the cohort
Table of Contents
European Urology Today June/July 2023
37
Powered by FlippingBook